Notre portefeuille de produits
Nos indications principales
Médicament
Préclinique
Phase 1
Phase 2
Phase 3
PDN / DHPB
Phase
Fezagepras (PBI-4050)
Respiratory Fibrotic Diseases e.g. Fibrose Pulmonaire Idiopathique (FPI)
GPR84 Antagonist
Undisclosed
Respiratory/GI
Undisclosed
NASH
Undisclosed
Kidney